MicroRNA as a Potential Diagnostic and Prognostic Biomarker in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis

IF 1.9 Q4 ONCOLOGY Cancer reports Pub Date : 2025-01-24 DOI:10.1002/cnr2.70070

Shaghayegh Khanmohammadi, Mahdi Masrour, Parisa Fallahtafti, Fatemeh Hasani

{"title":"MicroRNA as a Potential Diagnostic and Prognostic Biomarker in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis","authors":"Shaghayegh Khanmohammadi, Mahdi Masrour, Parisa Fallahtafti, Fatemeh Hasani","doi":"10.1002/cnr2.70070","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Recently, microRNAs (miRNAs) have been applied as biomarkers for diffuse large B-cell lymphoma (DLBCL) patients. Early diagnosis and management of DLBCL can improve patient survival and prognosis.</p>\n </section>\n \n <section>\n \n <h3> Aims</h3>\n \n <p>This systematic review and meta-analysis aimed to evaluate the diagnostic and prognostic accuracy of miRNA biomarkers in DLBCL patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We used the keywords “diffuse large B-cell lymphoma” and “microRNA” to search databases for original publications until June 14, 2023. Specificity, sensitivity, and AUC were used to assess diagnostic accuracy, and the prognostic value was assessed using the overall survival (OS) and progression-free survival (PFS) hazard ratio (HR). A subgroup analysis was performed based on the sample type acquired to investigate the heterogeneity.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Thirteen diagnostic and 33 prognostic studies were included from 839 articles. The Reitsma bivariate model estimated a sensitivity of 0.788 (95% CI: 0.733–0.834, <i>p <</i> 0.001), a specificity of 0.727 (95% CI: 0.654–0.790, <i>p <</i> 0.001), and an AUC of 0.824 in. The pooled AUC was 0.7385 (95% CI: 0.6847–0.7923, <i>p</i> < 0.0001). The pooled OS and PFS HRs (> 1) were 2.2847 (95% CI: 1.7248–3.0263, <i>p</i> < 0.0001) and 2.4883 (95% CI: 1.7367–3.5650, <i>p</i> < 0.0001). The pooled OS and PFS HRs (< 1) were 0.4965 (95% CI: 0.3576–0.6894, <i>p</i> < 0.0001) and 2.4883 (95% CI: 1.7367–3.5650, <i>p</i> < 0.0001). MiR-155 diagnostic values had a sensitivity of 0.710 (<i>p</i> > 0.1) and a specificity of 0.725 (<i>p</i> < 0.05), with an AUC of 0.776. miR-21 diagnostic values had an AUC of 0.8468 (<i>p</i> < 0.0001) and OS HR of 2.8938.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>MicroRNAs could serve as a powerful diagnostic and prognostic tool in DLBCL.</p>\n </section>\n </div>","PeriodicalId":9440,"journal":{"name":"Cancer reports","volume":"8 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760998/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cnr2.70070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Recently, microRNAs (miRNAs) have been applied as biomarkers for diffuse large B-cell lymphoma (DLBCL) patients. Early diagnosis and management of DLBCL can improve patient survival and prognosis.

Aims

This systematic review and meta-analysis aimed to evaluate the diagnostic and prognostic accuracy of miRNA biomarkers in DLBCL patients.

Methods

We used the keywords “diffuse large B-cell lymphoma” and “microRNA” to search databases for original publications until June 14, 2023. Specificity, sensitivity, and AUC were used to assess diagnostic accuracy, and the prognostic value was assessed using the overall survival (OS) and progression-free survival (PFS) hazard ratio (HR). A subgroup analysis was performed based on the sample type acquired to investigate the heterogeneity.

Results

Thirteen diagnostic and 33 prognostic studies were included from 839 articles. The Reitsma bivariate model estimated a sensitivity of 0.788 (95% CI: 0.733–0.834, p < 0.001), a specificity of 0.727 (95% CI: 0.654–0.790, p < 0.001), and an AUC of 0.824 in. The pooled AUC was 0.7385 (95% CI: 0.6847–0.7923, p < 0.0001). The pooled OS and PFS HRs (> 1) were 2.2847 (95% CI: 1.7248–3.0263, p < 0.0001) and 2.4883 (95% CI: 1.7367–3.5650, p < 0.0001). The pooled OS and PFS HRs (< 1) were 0.4965 (95% CI: 0.3576–0.6894, p < 0.0001) and 2.4883 (95% CI: 1.7367–3.5650, p < 0.0001). MiR-155 diagnostic values had a sensitivity of 0.710 (p > 0.1) and a specificity of 0.725 (p < 0.05), with an AUC of 0.776. miR-21 diagnostic values had an AUC of 0.8468 (p < 0.0001) and OS HR of 2.8938.

Conclusion

MicroRNAs could serve as a powerful diagnostic and prognostic tool in DLBCL.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

MicroRNA作为弥漫性大b细胞淋巴瘤的潜在诊断和预后生物标志物：一项系统综述和荟萃分析

背景：最近，microRNAs （miRNAs）被用作弥漫性大b细胞淋巴瘤（DLBCL）患者的生物标志物。DLBCL的早期诊断和治疗可以改善患者的生存和预后。目的：本系统综述和荟萃分析旨在评估miRNA生物标志物在DLBCL患者中的诊断和预后准确性。方法：使用关键词“弥漫性大b细胞淋巴瘤”和“microRNA”检索数据库，检索至2023年6月14日的原始出版物。使用特异性、敏感性和AUC来评估诊断准确性，并使用总生存期（OS）和无进展生存期（PFS）风险比（HR）评估预后价值。根据获得的样本类型进行亚组分析以调查异质性。结果：从839篇文章中纳入了13项诊断研究和33项预后研究。Reitsma双变量模型估计敏感性为0.788 (95% CI: 0.733-0.834, p < 0.001)，特异性为0.727 (95% CI: 0.654-0.790, p < 0.001)， AUC为0.824。合并AUC为0.7385 （95% CI: 0.6847 ~ 0.7923, p < 1）、2.2847 (95% CI: 1.7248 ~ 3.0263, p < 0.1)，特异性为0.725 （p < 1）。结论：microrna可作为DLBCL的有力诊断和预后工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊